Microbot Medical Inc. (MBOT)

NASDAQ: MBOT · IEX Real-Time Price · USD
1.230
+0.080 (6.96%)
At close: Mar 28, 2024, 4:00 PM
1.300
+0.070 (5.69%)
After-hours: Mar 28, 2024, 4:33 PM EDT

Company Description

Microbot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom.

It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space.

The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.

In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.

The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development.

Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

Microbot Medical Inc.
Microbot Medical logo
Country United States
Founded 2010
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 18
CEO Harel Gadot

Contact Details

Address:
25 Recreation Park Dr Suite 108
Hingham, Massachusetts 02043
United States
Phone 908-938-5561
Website microbotmedical.com

Stock Details

Ticker Symbol MBOT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000883975
CUSIP Number 59503A204
ISIN Number US59503A2042
Employer ID 94-3078125
SIC Code 3841

Key Executives

Name Position
Harel Gadot Co-Founder, President, Chief Executive Officer and Chairman
Yoseph Bornstein Co-Founder and Independent Director
Rachel Vaknin Chief Financial Officer
Dr. Simon Sharon MBA, MSc Chief Technology Officer and GM of Microbot Israel
Dr. Juan Diaz-Cartelle Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 27, 2024 10-K Annual Report
Feb 27, 2024 8-K Current Report
Feb 20, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 30, 2024 424B3 Prospectus
Jan 30, 2024 8-K Current Report
Jan 25, 2024 EFFECT Notice of Effectiveness
Jan 22, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jan 19, 2024 UPLOAD Filing
Jan 18, 2024 8-K Current Report